HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway
Alison Smith(Memorial Sloan Kettering Cancer Center), Sarat Chandarlapaty(Memorial Sloan Kettering Cancer Center)
Cited by 86
Related Papers
Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
|Oncogene|2016|430
KMT2C mediates the estrogen dependence of breast cancer through regulation of ERα enhancer function
|Oncogene|2018|149
Mutant SF3B1 promotes AKT- and NF-κB–driven mammary tumorigenesis
|Journal of Clinical Investigation|2020|45
Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion
|Cancer Cell|2024|44
EGFR-directed antibodies promote HER2 ADC internalization and efficacy
|Cell Reports Medicine|2024|27